Solubility and stability are amongst the factors contributing to the therapeutic efficacy of biologics. Human antibody heavy chain variable domains, VHs, are one class of biologics; improving VH biophysical properties is the focus of significant protein engineering efforts. Here, we describe an efficacy engineering approach which involves the introduction of a disulfide linkage in the VH core and which improves both VH solubility and stability. More specifically, we describe protocols for generation of disulfide engineered human VHs and their characterization in terms of disulfide linkage formation, non-aggregation, and stability. Our solubility/stability engineering approach may be applied to other VHs. \ua9 2012 Springer Science+Business ...
Improving the stability of proteins is an important goal in many biomedical and industrial applicati...
Human antibodies represent about half of all drugs entering clinical trials. Target interaction is m...
Monoclonal antibody mAb 03/01/01, directed against the musk odorant traseolide, carries a serine res...
Monoclonal antibodies are a remarkably successful class of therapeutics used to treat a wide range o...
Recombinant antibody fragments are significant therapeutic and diagnostic reagents. As such, their e...
We have previously shown that incorporation of a second intradomain disulfide linkage into camelid V...
When panned with a transient heat denaturation approach against target enzymes, a human V(H) (antibo...
The use of VH domains in diagnostic and therapeutic applications circumvents many of the issues asso...
Human immunoglobulin heavy chain variable domains (VH) are promising scaffolds for antigen binding. ...
Human immunoglobulin heavy chain variable domains (VH) are promising scaffolds for antigen binding. ...
We set out to gain deeper insight into the potential of antibody light chain variable domains (VLs) ...
Single-domain VHH antibodies are promising reagents for medical therapy. A conserved disulfide bond ...
We have constructed a human VH library based on a camelized VH sequence. The library was constructed...
<div><p>Human immunoglobulin heavy chain variable domains (V<sub>H</sub>) are promising scaffolds fo...
There are great demands on the stability, expression yield and resistance to aggregation of antibody...
Improving the stability of proteins is an important goal in many biomedical and industrial applicati...
Human antibodies represent about half of all drugs entering clinical trials. Target interaction is m...
Monoclonal antibody mAb 03/01/01, directed against the musk odorant traseolide, carries a serine res...
Monoclonal antibodies are a remarkably successful class of therapeutics used to treat a wide range o...
Recombinant antibody fragments are significant therapeutic and diagnostic reagents. As such, their e...
We have previously shown that incorporation of a second intradomain disulfide linkage into camelid V...
When panned with a transient heat denaturation approach against target enzymes, a human V(H) (antibo...
The use of VH domains in diagnostic and therapeutic applications circumvents many of the issues asso...
Human immunoglobulin heavy chain variable domains (VH) are promising scaffolds for antigen binding. ...
Human immunoglobulin heavy chain variable domains (VH) are promising scaffolds for antigen binding. ...
We set out to gain deeper insight into the potential of antibody light chain variable domains (VLs) ...
Single-domain VHH antibodies are promising reagents for medical therapy. A conserved disulfide bond ...
We have constructed a human VH library based on a camelized VH sequence. The library was constructed...
<div><p>Human immunoglobulin heavy chain variable domains (V<sub>H</sub>) are promising scaffolds fo...
There are great demands on the stability, expression yield and resistance to aggregation of antibody...
Improving the stability of proteins is an important goal in many biomedical and industrial applicati...
Human antibodies represent about half of all drugs entering clinical trials. Target interaction is m...
Monoclonal antibody mAb 03/01/01, directed against the musk odorant traseolide, carries a serine res...